



LKT Laboratories, Inc.

Dabrafenib

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information

Product ID D0004

CAS No. 1195765-45-7

Chemical Name

Synonym GSK2118436A

Formula $C_{23}H_{20}F_3N_5O_2S_2$

Formula Wt. 519.56

Melting Point

Purity $\geq 98\%$


Solubility soluble in DMSO

Store Temp $-20^{\circ}C$

Ship Temp Ambient

Description

Dabrafenib is a reversible kinase inhibitor with anticancer chemotherapeutic activity. This compound is selective primarily for mutant (V600E) B-Raf, but has also inhibited tumor growth in cells expressing other B-Raf mutants (V600K, V600D) and WT B-Raf. Dabrafenib is partially active against c-Raf as well. Dabrafenib is an ATP-competitive inhibitor that has been approved for clinical use in the treatment of unresectable or metastatic melanomas; it is also being examined for treatment of brain metastases and other cancers. This compound has a very high oral bioavailability.



Bulk quantities available upon request

Product ID Size

D0004 5 mg

D0004 25 mg

D0004 100 mg

References Ballantyne AD, Garnock-Jones KP. Dabrafenib: First Global Approval. *Drugs*. 2013 Jul 24. [Epub ahead of print] PMID: 23881668.

Huang T, Karsy M, Zhuge J, et al. B-Raf and the inhibitors: from bench to bedside. *J Hematol Oncol*. 2013 Apr 25;6:30. PMID: 23617957.

Klinac D, Gray ES, Millward M, et al. Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. *Front Oncol*. 2013;3:54. PMID: 23515890.

Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. *Lancet*. 2012 Jul 28;380(9839):358-65. PMID: 22735384.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.